Tacrolimus Extended Release could be an Alternative to the use of Cyclosporine after Allogeneic HSCT in case of Renal Impairment due to Cyclosporine: A Prospective pilot study from two centers in France
Marie Y. Detrait(Hôpital Civil de Charleroi), Fiorenza Barraco(Hôpital Lyon Sud), Vérane Schwiertz(Hospices Civils de Lyon), Valerie Chapel, Cécile Pochon(Université de Lorraine), Stéphane Morisset(Lyon 1 Université), Catherine Rioufol(Lyon 1 Université), Sylvie Tarillon, Aurrore Perrot, Maud D’Aveni(Centre National de la Recherche Scientifique), Nicolas Vantard(Hospices Civils de Lyon), M Michallet, M-T Rubio, M. Manchón, Grepin GR, S Cohen, Notarantonio AB
Cited by 0
Related Papers
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
|Blood|2022|212
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation
|Bone Marrow Transplantation|2014|148